Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — 2020 ASX Small & Mid-Cap Virtual Conference
20 slides from Botanix Pharmaceuticals's conference presentation, Sep 8, 2020
Slide 1: New antimicrobial data and conference presentation
8 September 2020 New antimicrobial data and conference presentation Key highlights • New data demonstrates BTX 1801 eliminates methicillin-resistant Staphylococcus aureus (‘MRSA’ or ‘Golden Staph’) from human skin explants infected with MRSA • New data also confirms synthetic CBD’s novel mechanism o
Slide 2: Human Skin Study results and safety
The Human Skin Study showed that by 24 hours all concentrations of CBD in the BTX 1801 ointment resulted in significant reductions (p <0.05) from the growth control. The data from the Human Skin Study supports results previously reported by Botanix using explants from porcine skin and further valida
Slide 3: Mechanism of action and Phase 2a study update
Figure 3 shows that treatment with synthetic cannabidiol resulted in disruption of the bacterial membrane (allowing the green dye to permeate the cytoplasmic membrane of Staph) resulting in cell death and prevention of bacterial growth and multiplication. Conversely, the negative control shows that
Slide 4: About Botanix Pharmaceuticals
About Botanix Pharmaceuticals Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage synthetic cannabinoid company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomi
Slide 5: Investor Presentation
Unlocking the potential of synthetic cannabinoids ASX Small & Mid-Cap Conference – ‘On-Demand’ Investor Presentation September 2020 1
Slide 6: Investment Highlights
Investment Highlights Pharma focused Leading pharmaceutical company leveraging unique properties of synthetic cannabinoids, including cannabidiol (CBD) Antimicrobial opportunities Dermatology opportunities Novel antimicrobial platform with positive Targeting key dermatology indications with pre-clin
Slide 7: Synthetic Cannabinoids are suited to treat Skin Diseases and Infections
Pharma focused Synthetic Cannabinoids are suited to treat Skin Diseases and Infections Botanix’s studies show synthetic cannabinoids: ✓ Safe and well tolerated ✓ Broad anti-inflammatory properties relevant to infections ✓ Strong and consistent impact on inflammatory lesions ✓ Kills S. aureus and res
Slide 8: Synthetic Cannabinoids Advanced Clinical Pipeline
Pharma focused Synthetic Cannabinoids Advanced Clinical Pipeline Ph 1 Ph 1b Ph 2 Ph 3 Status Planning underway BTX 1503 for Phase 3 clinical Acne studies BTX 1801 Phase 2a recruitment Antimicrobial commenced Ready to commence BTX 1702 Phase 2 once COVID- Rosacea 19 restrictions ease www.botanixpharm
Slide 9: Antimicrobial Resistance is a Fast-Growing Problem
ANTIMICROBIAL Antimicrobial Resistance How does AMR develop? is a Fast-Growing Problem ❖ Exposure to antibiotics leaves only drug-resistant bacteria ❖ Repeat exposure builds resistance and limits drug efficacy Global forecast deaths by 20501 (p.a.) ❖ “Superbugs” emerge increasing morbidity and morta
Slide 10: Encouraging new pre-clinical data
ANTIMICROBIAL Encouraging new pre-clinical data Human explant data demonstrates BTX 1801 eliminates MRSA from infected human skin Human Skin Explant Model Efficacy of different concentrations of BTX 1801 in MRSA infected human skin explants Freshly sourced Shave skin and Cut 5mm 1 Hour 3 Hours 24 Ho
Slide 11: Novel Mechanism of Action Confirmed
ANTIMICROBIAL Novel Mechanism of Action Confirmed The time-lapse shows CBD causes rapid permeabilization of the bacterial membrane and cell death S.aureus treated with 2.5% methanol (negative control) 1 S.aureus treated with synthetic cannabidiol1 Staph bacteria treated Staph bacteria treated with n
Slide 12: Surgical Site Infections (SSI) Indication: Significant Demand From Key Stakeholders
ANTIMICROBIAL Surgical Site Infections (SSI) Indication: Patients Significant Demand From Key Stakeholders ✓ SSIs are considered the most frequent complication in surgical patients1 ✓ Prevention of SSIs reduces patient mortality and morbidity ✓ SSIs constitute a financial burden on patients and nega
Slide 13: BTX 1801: Clinical Development Strategy
ANTIMICROBIAL BTX 1801: Clinical Development Strategy Study update Study design ✓ Recruitment of Phase 2a study has commenced and will be ❖ Double-blind, vehicle-controlled Phase 2a clinical study conducted wholly in Western Australia ❖ 4 dose groups: ~60 healthy volunteers: ❖ Study evaluates safety
Slide 14: BTX 1503: Successful End-of-Phase FDA Meeting
DERMATOLOGY BTX 1503: Successful End-of-Phase 2 FDA Meeting Study update Sizable acne prescription market ✓ End of Phase 2 meeting with FDA successfully completed The global acne market expected to reach US$7bn by 2024 ✓ FDA highlighted excellent safety profile of BTX 1503, and allowed several waive
Slide 15: BTX 1702: Impact of Rosacea and Significant Market Opportunity
DERMATOLOGY BTX 1702: Impact of Rosacea and Significant Market Opportunity ❖ Papulopustular rosacea is a A rapidly growing market chronic skin disease Rosacea market projected to grow to US$2.6bn by 20253 characterised by redness (inflammation) and acne- US$2.6bn like-break-outs1 Anticipated to regi
Slide 16: BTX 1702: Rosacea Study Primed to Kick Off
DERMATOLOGY BTX 1702: Rosacea Study Primed to Kick Off Study update Study design ✓ BTX 1702 ethics approval received ❖ Four dose groups, ~120 patients: ✓ Study preparations underway to ensure enrolment can process safely and efficiently when ready – BTX 1702 Formulation A - twice daily: 30 patients
Slide 17: World-Class Team
WORLD-CLASS TEAM World-Class Team Board Vince Ippolito Matt Callahan Dr Michael Thurn Dr Stewart Washer Dr Bill Bosch President and Executive Chairman Executive Director Executive Director Director Executive Director ❖ COO of Anacor and Medicis with 17 ❖ Serial founder and ex-investment ❖ Previous M
Slide 18: Executing on Key Near-Term Milestones
NEAR-TERM CATALYSTS Executing on Key Near-Term Milestones ❖ Antimicrobial: BTX 1801 Phase 2a study completion Targeting completion of the study in 4Q CY2020 – December 2020 ❖ Acne: BTX 1503 planning for Phase 3 clinical studies Timetable for progression of Phase 3 is pending the completion of BTX 17
Slide 19: Disclaimer
Disclaimer Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate, ”expect,” “intend,” “may,” “plan,” “predict,” “project,” “target, ”
Slide 20: General enquiries
General enquiries Botanix Pharmaceuticals Corporate communications +61 8 6555 2945 investors@botanixpharma.com www.botanixpharma.com Botanix Pharmaceuticals Ltd (ASX:BOT)
Botanix Pharmaceuticals — 2020 ASX Small & Mid-Cap Virtual Conference on 6ix